Anbio Biotechnology
corporate_fare Company Profile
Anbio Biotechnology (NASDAQ:NNNN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for NNNN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-19, rated 9/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for NNNN spans 6-K, 20-F.
Recent high-impact activity:
- Shareholders Approve Drastic Capital Restructuring: Reverse Split, Trillions in New Shares, and Enhanced Insider Control
- Shareholders to Vote on Reverse Split, Massive Share Authorization, and Super-Voting Share Entrenchment
- Anbio Biotechnology Reports Strong 2025 Net Income & Gross Margin Amidst Cash Burn and Auditor Change
- Anbio Biotechnology Changes Auditor Due to Capacity Concerns, Appoints GGF CPA LTD
- Anbio Biotechnology Appoints Michael Zhang as Independent Director and Audit Committee Chair
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 51,672 shares in NNNN as of the September 15, 2026 settlement, a 11.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 55.9% of NNNN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for NNNN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-09.
Shelf Registration Filed · No Immediate Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NNNN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.